8/102 sources · 2 publishersUpdated Oct 8, 16:32 UTC
TELA Bio obtains FDA 510(k) clearance for Liora resorbable surgical mesh
TELA Bio announced that the U.S. Food and Drug Administration granted 510(k) clearance for its Liora Monofilament Scaffold, a fully resorbable surgical mesh for soft‑tissue reinforcement. The announcement was made on October 5, 2026. The product was developed in‑house and is the first fully resorbable synthetic device in the company's portfolio, according to CEO Heather Getz. TELA Bio will provide further details during its third‑quarter earnings call in early November.
Why it matters
The clearance permits TELA Bio to market Liora, expanding its product portfolio and potentially increasing sales in the soft‑tissue reconstruction market.
Key facts
- 1The U.S. Food and Drug Administration granted 510(k) clearance for Liora Monofilament Scaffold. globenewswire.com
- 2The announcement was released on October 5, 2026. globenewswire.com
- 3Liora is a fully resorbable surgical mesh for soft tissue reinforcement. globenewswire.com
- 4The product was developed in‑house and is the first fully resorbable synthetic product in TELA Bio's portfolio. globenewswire.com
- 5Heather Getz, CEO of TELA Bio, said the clearance is a significant milestone for the company. globenewswire.com
- 6TELA Bio will discuss the clearance in its third‑quarter earnings call expected in early November. globenewswire.com
Summary written by AlphAI from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.